Company: DARE
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001401914-25-000022
Chunk: 91

Company: Dare Bioscience, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 2
Chunk 91
---
 (expense)202,811 (732,883)935,694 (128)%Net loss$(4,378,307)$(6,755,356)$2,377,049 (35)%Other comprehensive loss:Foreign currency translation adjustments13,090 (39,227)52,317 (133)%Comprehensive loss$(4,365,217)$(6,794,583)$2,429,366 (36)%

Revenues

Revenues for the three months ended March 31, 2025 and March 31, 2024 are related to our license agreement with Organon to commercialize XACIATO. From and after April 1, 2024, any revenue we recognize under such license agreement will be recognized as non-cash royalty revenue. See "—Financial Overview—Revenue," above for information.

General and administrative expenses

The decrease of approximately $0.4 million in general and administrative expenses for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024 was primarily attributable to decreases in (i) stock-based compensation expense of approximately $0.2 million, (ii) professional services expense of approximately $0.1 million, and (iii) personnel costs of approximately $0.1 million. 

Research and development expenses

The following table summarizes our R&D expenses for the periods indicated, together with the changes in those items in terms of dollars and percentage:

35

Three Months EndedMarch 31,Change20252024$%Direct program costs:Ovaprene (1)$1,495,727 $2,183,873 $(688,146)(32)%Sildenafil Cream, 3.6%211,389 460,107 (248,718)(54)%Other advanced clinical stage programs490,562 446,671 43,891 10 %Phase 1 and Phase 1-ready clinical stage programs (1)496,747 229,550 267,197 116 %Preclinical stage programs (1)1,098,738 1,371,708 (272,970)(20)%Other development programs— 12,794 (12,794)(100)%Contra R&D expenses (2)(2,618,373)(2,652,715)34,342 (1)%Total direct program costs1,174,790 2,051,988 (877